Question: how long has saxagliptin been on the market?
Answer: Approved by the FDA in 2009 under the trade name Onglyza (Bristol-Myers Squibb/AstraZeneca), saxagliptin is the second DPP-4 inhibitor in the market. It is taken in the dosage of 2.5–5 mg/day orally.